Evidence map›Paper›PMID 24562642›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2014

Staging the axilla in breast cancer patients with ¹⁸F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?

Dimitri Bellevre, Cécile Blanc Fournier, Odile Switsers, Audrey Emmanuelle Dugué, Christelle Levy, Djelila Allouache, Cédric Desmonts, Hubert Crouet, Jean-Marc Guilloit, Jean-Michel Grellard and 1 more

Abstract readValidation Study
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024
    Guideline
  2. Pooled it
  3. Article
  4. Diagnostic accuracy of dual-phaseScientific reports · 2025
    Article
  5. [Insights into imaging · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Is it time to include [European journal of nuclear medicine and molecular imaging · 2021
    Article
  10. Lymph Node Staging with a Combined Protocol ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Article
  11. New PET technologies - embracing progress and pushing the limits.European journal of nuclear medicine and molecular imaging · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Diagnostic performance ofCancer imaging : the official publication of the International Cancer Imaging Society · 2018
    Article
  17. Article
  18. Article
  19. Review
  20. Quantification, improvement, and harmonization of small lesion detection with state-of-the-art PET.European journal of nuclear medicine and molecular imaging · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dimitri BellevreNuclear Medicine Department, François Baclesse Cancer Centre, Avenue Général Harris, 14076, Cedex 5, Caen, France.
Cécile Blanc Fournier
Odile Switsers
Audrey Emmanuelle Dugué
Christelle Levy
Djelila Allouache
Cédric Desmonts
Hubert Crouet
Jean-Marc Guilloit
Jean-Michel Grellard
Nicolas Aide

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePoint spread function (PSF) reconstruction improves spatial resolution throughout the entire field of view of a PET system and can detect smaller metastatic deposits than conventional algorithms such as OSEM. We assessed the impact of PSF reconstruction on quantitative values and diagnostic accuracy for axillary staging of breast cancer patients, compared with an OSEM reconstruction, with emphasis on the size of nodal metastases.

methodsThis was a prospective study in a single referral centre in which 50 patients underwent an (18)F-FDG PET examination before axillary lymph node dissection. PET data were reconstructed with an OSEM algorithm and PSF reconstruction, analysed blindly and validated by a pathologist who measured the largest nodal metastasis per axilla. This size was used to evaluate PET diagnostic performance.

resultsOn pathology, 34 patients (68%) had nodal involvement. Overall, the median size of the largest nodal metastasis per axilla was 7 mm (range 0.5 - 40 mm). PSF reconstruction detected more involved nodes than OSEM reconstruction (p = 0.003). The mean PSF to OSEM SUVmax ratio was 1.66 (95 % CI 1.01 - 2.32). The sensitivities of PSF and OSEM reconstructions were, respectively, 96% and 92% in patients with a largest nodal metastasis of >7 mm, 60% and 40% in patients with a largest nodal metastasis of ≤7 mm, and 92% and 69% in patients with a primary tumour ≤30 mm. Biggerstaff graphical comparison showed that globally PSF reconstruction was superior to OSEM reconstruction. The median sizes of the largest nodal metastasis in patients with nodal involvement not detected by either PSF or OSEM reconstruction, detected by PSF but not by OSEM reconstruction and detected by both reconstructions were 3, 6 and 16 mm (p = 0.0064) respectively. In patients with nodal involvement detected by PSF reconstruction but not by OSEM reconstruction, the smallest detectable metastasis was 1.8 mm.

conclusionAs a result of better activity recovery, PET with PSF reconstruction performed better than PET with OSEM reconstruction in detecting nodal metastases ≤7 mm. However, its sensitivity is still insufficient for it to replace surgical approaches for axillary staging. PET with PSF reconstruction could be used to perform sentinel node biopsy more safely in patients with a primary tumour ≤30 mm and with unremarkable PET results in the axilla.

Indexed as

Fluorodeoxyglucose F18Positron-Emission TomographyRadiopharmaceuticalsAlgorithmsAxillaBreast NeoplasmsCarcinoma, Ductal, BreastFemaleHumansImage Processing, Computer-AssistedLimit of DetectionLymphatic MetastasisMiddle AgedMultimodal ImagingTomography, X-Ray ComputedFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID24562642
PMCPMC4006125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.